Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 4/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | CPT1A | P50416 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2001530 | 0.91 | CRHBP (0.44) | KMT2ASMN1; SMN2RORCNR1H3NR1H2 | |
| SCHEMBL2004171 | 0.86 | EPHX2 (0.47) | POLBRORCNR1H3NR1H2HPGD | |
| SCHEMBL2001989 | 0.86 | HPGD (0.48) | KMT2APOLBLMNARORCNR1H3 | |
| SCHEMBL2002839 | 0.85 | RORC (0.48) | RORCNR1H3NR1H2CPT1AMAPT | |
| SCHEMBL12570135 | 0.85 | RORC (0.44) | RORCNR1H3NR1H2CPT1AMAPT | |
| SCHEMBL2006881 | 0.84 | RORC (0.42) | SMN1; SMN2RORCNR1H3NR1H2CPT1A | |
| SCHEMBL2006883 | 0.84 | RORC (0.42) | SMN1; SMN2RORCNR1H3NR1H2CPT1A | |
| SCHEMBL2000444 | 0.84 | RORC (0.49) | RORCNR1H3NR1H2CPT1AGAA | |
| SCHEMBL2002378 | 0.83 | LMNA (0.47) | LMNARORCNR1H3NR1H2CPT1A | |
| SCHEMBL2002379 | 0.83 | LMNA (0.47) | LMNARORCNR1H3NR1H2CPT1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960377-B2 | Substituted pyridoxazines | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | claimed |
| US-7960377-B2 | Substituted pyridoxazines | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960377-B2 | Substituted pyridoxazines | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| WO-2009120660-A2 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CNR1, CNR2, TRPV1 | KMT2A 3804/4885POLB 3140/4885LMNA 3572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.